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Summary
Background Once-daily topical oxymetazoline cream 10% significantly reduced per-
sistent facial erythema of rosacea in trials requiring live, static patient assessments.
Objectives To evaluate critically the methodology of clinical trials that require live,
static patient assessments by determining whether assessment of erythema is dif-
ferent when reference to the baseline photograph is allowed.
Methods In two identically designed, randomized, phase III trials, adults with per-
sistent facial erythema of rosacea applied oxymetazoline or vehicle once daily.
This phase IV study evaluated standardized digital facial photographs from the
phase III trials to record ≥ 1-grade Clinician Erythema Assessment (CEA)
improvement at 1, 3, 6, 9 and 12 h postdose.
Results Among 835 patients (oxymetazoline n = 415, vehicle n = 420), significantly
greater proportions of patients treated with oxymetazoline vs. vehicle achieved ≥ 1-
grade CEA improvement. For the comparison between phase IV study results and the
original phase III analysis, when reference to baseline photographs was allowed while
evaluating post-treatment photographs, the results for oxymetazoline were similar to
results of the phase III trials (up to 85.7%), but a significantly lower proportion of
vehicle recipients achieved ≥ 1-grade CEA improvement (up to 29.7% [phase 4] vs.
52.3% [phase 3]; P<0.001). In the phase IV study, up to 802% of patients treated with
oxymetazoline achieved at least moderate erythema improvement vs. up to 229% of
patients treated with vehicle. The association between patients’ satisfaction with facial
skin redness and percentage of erythema improvement was statistically significant.
Conclusions Assessment of study photographs, with comparison to baseline, confirmed
significant erythema reduction with oxymetazoline on the first day of application.
Compared with the phase III trial results, significantly fewer vehicle recipients attained
≥ 1-grade CEA improvement, suggesting a mitigated vehicle effect. This methodology
may improve the accuracy of clinical trials evaluating erythema severity.
© 2018 The Authors. British Journal of Dermatology
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What’s already known about this topic?
• Phase III studies that evaluate the effects of medications on persistent facial
erythema associated with rosacea require investigator assessments without allowing
comparison with baseline images.
What does this study add?
• Grading of facial erythema of rosacea that utilized baseline photographs compared
with post-treatment photographs enhanced the accuracy of persistent facial
erythema assessments.
• Furthermore, this method more accurately differentiated active treatment with
oxymetazoline cream 10% from vehicle compared with live, static assessments.
• Methodology that allows for comparison to baseline photographs may improve the
accuracy of clinical trials that evaluate erythema severity.
Reduction of persistent facial erythema, which is the most
common and bothersome sign of rosacea, is an important
objective in the clinical management of rosacea.1–4 This clini-
cally evident manifestation of rosacea is associated with a sub-
stantial burden of illness,5,6 and rosacea therapies that offer
immediate, visible erythema reduction may lead to better
patient-reported outcomes and quality of life. Topical a-adre-
nergic receptor agonists, which target vascular mechanisms
involved in the development of erythema associated with rosa-
cea,7 can significantly reduce persistent facial erythema,
according to published clinical trials.8–10
Once-daily topical oxymetazoline hydrochloride cream
10% (oxymetazoline; Rhofade, Allergan plc, Dublin, Ireland)
is an a1A-adrenoceptor agonist approved to treat persistent
facial erythema associated with rosacea in adults.11 Two pre-
viously published, identically designed, pivotal, phase III,
vehicle-controlled trials (REVEAL)8,9,12 demonstrated that
oxymetazoline applied once daily for 29 days significantly
improved moderate-to-severe persistent facial erythema com-
pared with vehicle. Efficacy assessments were performed using
the Clinician Erythema Assessment (CEA) scale with photonu-
meric guide, which provided a static assessment of overall
facial erythema based on the actual appearance of the face on
the day of evaluation without relying on prior memory, per-
ception, or assessment of change from previous assessments,
in accordance with guidelines issued by the U.S. Food and
Drug Administration.13–15 Thus, in assigning a CEA score to
patients’ facial erythema during efficacy assessments, investiga-
tors did not refer to photographs taken at baseline or during
other study visits.
A phase IV study was conducted to determine whether
allowing investigators to refer to baseline photographs while
evaluating post-treatment photographs from the two phase III
trials would yield differences in CEA score assessment for the
post-treatment time points, and to quantify the magnitude of
erythema improvement via assessment of percentage of
erythema reduction. The CEA scale is well suited for this use
because it was developed in consultation with dermatologists
specializing in rosacea, and was designed to detect readily
apparent and clinically different degrees of facial erythema
(data on file, Allergan plc, Irvine, CA, U.S.A.).
Patients and methods
Phase III trials
The methods of the phase III trials from which the pho-
tographs were obtained have been published previously; they
are briefly summarized here.8,9 The studies were approved by
the Quorum Review institutional review board and were con-
ducted in accordance with the ethical standards of the review
board and with the Declaration of Helsinki.
Two identically designed, phase III, randomized, multicen-
tre, double-blind, parallel-group, vehicle-controlled trials were
conducted in the U.S.A., namely REVEAL trial 1 (ClinicalTri-
als.gov identifier NCT02131636) and REVEAL trial 2 (Clini-
calTrials.gov identifier NCT02132117). The studies enrolled
adults aged 18 years and older with moderate-to-severe persis-
tent facial erythema associated with rosacea.8,9 Patients in both
studies were randomized 1 : 1 to topical application of
oxymetazoline or vehicle cream once each morning. They
were instructed to apply a pea-sized amount of medication in
a thin layer covering the entire face.
CEA was assessed in patients predose and 1, 3, 6, 9 and
12 h postdose at study visits. Standardized digital photographs
(Canfield Scientific, Inc., Parsippany, NJ, U.S.A.) were
obtained at each time point after assessments were completed.
Phase IV study
The present study included treated patients who had a com-
plete set of photographs and data for all assessment time
© 2018 The Authors. British Journal of Dermatology
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points on day 1 in the phase III trials and consented in writ-
ing to the use of their photographs for research purposes.
Image review
A total of 10 highly experienced board-certified dermatologists
participated in a consensus training session on the use of the
CEA with a photo guide using sample photographs before
study evaluations occurred. Physicians provided their evalua-
tions of the sample photographs and training was repeated, if
necessary, until they achieved consensus. Upon completion of
training, the investigators independently reviewed a unique
set of patient photographs from day 1 before treatment appli-
cation (baseline) and postdose at 1, 3, 6, 9 and 12 h. Investi-
gators were blinded to the treatment received by patients in
the photographs and to the postdose time points. A high-reso-
lution monitor (Canfield Scientific, Parsippany, NJ, U.S.A.)
displayed the baseline photograph for initial assessment, then
displayed the baseline photograph alongside each postdose
photograph (Fig. S1; see Supporting Information). Investiga-
tors entered assessments for each photograph using a touch-
screen tablet.
Efficacy assessments
The primary efficacy analysis was the proportion of patients
who achieved at least a 1-grade improvement on the 5-point
CEA scale with photonumeric guide (0, clear; 1, almost clear;
2, mild erythema; 3, moderate erythema; 4, severe erythema)
from baseline at 1, 3, 6, 9, and 12 h postdose (Table S1; see
Supporting Information). In addition, investigators compared
the erythema severity between the baseline photograph and
the post-treatment photographs and determined the percentage
of erythema reduction using the following scale: 0, none;
~25%, mild; ~50%, moderate; ~75%, marked; ~95%, com-
plete clearing.
Additional analyses
Patient satisfaction
In the phase III trials, patient satisfaction with the appearance
of facial skin redness was assessed using item 1 of the vali-
dated 10-item Satisfaction Assessment for Rosacea Facial Red-
ness (SAT-RFR) questionnaire at 3, 6, 9 and 12 h postdose.
The patients responded using a 5-point scale that ranged from
0 (very dissatisfied) to 4 (very satisfied). The present analysis
examined the association between the patients’ satisfaction
with the appearance of their facial skin redness in the phase
III trials and the investigator-assessed percentage improvement
in erythema in the phase IV study.
Fitzpatrick skin phototype
CEA improvement of at least one grade was assessed using
Fitzpatrick skin phototypes I–III and IV–VI.
Worsening of erythema
The number and proportion of patients in the photographic
assessments who had ≥ 1-grade CEA increase (worsening)
with either oxymetazoline or vehicle were evaluated.
Statistical analysis
Pairwise analyses between postdose time points and the day-1
predose time point (baseline) were conducted on the per-pro-
tocol population, which consisted of patients with complete
datasets for all time points. The data were summarized using
descriptive statistics. P-values were adjusted for multiple com-
parisons using the Hochberg method to control the family-
wise error rate.16
For comparative and correlational analyses between the
phase III and the phase IV datasets, these datasets were rela-
tionally merged (merged population). No imputation of miss-
ing data was utilized. Correlations between percentage
improvement categories and SAT-RFR item 1 were conducted
on the per-protocol sample based on the Spearman rank corre-
lation coefficient. Comparisons between treatment arms in the
phase IV study and the phase III trials were calculated using
the McNemar paired test. All analyses were performed using R
version 3.4.3 or greater (The R Foundation for Statistical
Computing).
Results
Patients
A total of 835 patients (oxymetazoline n = 415, vehicle
n = 420) were included. The mean age was 499 years, and
the majority of patients were female (798%) and had Fitz-
patrick skin phototype II (504%) or III (301%) (Table S2;
see Supporting Information). The merged population assessed
in comparisons and correlations between the phase IV and
phase III datasets comprised 814 patients (oxymetazoline,
n = 407; vehicle, n = 407). Baseline characteristics of the
patients in the phase III trials (trial 1, N = 440; trial 2,
N = 445; combined N = 885) have been published previ-
ously.8,9
Efficacy
In the photographic assessments, a significantly greater pro-
portion of patients treated with oxymetazoline than those trea-
ted with vehicle achieved at least a 1-grade CEA improvement
from baseline (P < 0001 for the comparison with vehicle at
all postdose time points. Fig. S2; see Supporting Information).
At 1 h, these proportions were 549% of patients in the
oxymetazoline group compared with 179% of patients in the
vehicle group; at 3 h, 853% vs. 267%; at 6 h, 841% vs.
288%; at 9 h, 747% vs. 298% and at 12 h, 653% vs.
276%. There was up to a 586 percentage-point difference
© 2018 The Authors. British Journal of Dermatology
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between the oxymetazoline and vehicle groups in the propor-
tion of patients who achieved this milestone.
The proportion of patients in the oxymetazoline arm who
achieved at least a 1-grade CEA improvement from baseline in
the phase IV study, in which investigators were allowed to refer
to the baseline photograph while evaluating post-treatment pho-
tographs, was not significantly different from that in the phase III
trials, which required live, static assessments (Fig. 1). However,
a significantly lower proportion of patients treated with vehicle
had at least a 1-grade CEA improvement when reference to the
baseline photograph was allowed compared with the proportion
when live, static assessments were required (P < 0001 for 1 h
and 12 h; P < 00001 for 3 h, 6 h and 9 h).
Figure 2 shows representative photographs of patients eval-
uated in this study. The patient treated with oxymetazoline
(Fig. 2a) achieved at least a 1-grade CEA improvement from
baseline, whereas the patient treated with vehicle (Fig. 2b)
did not. The CEA ratings for the patient treated with oxymeta-
zoline were consistent regardless of the investigator’s ability to
see the baseline photograph, whereas the apparent treatment
effect in the patient who received vehicle was not noted when
reference to the baseline photograph was allowed.
At least a moderate improvement (~50% or greater) in per-
sistent erythema was noted in a significantly higher proportion
of patients treated with oxymetazoline than those who
received vehicle (P < 0001) (Fig. S3; see Supporting Informa-
tion). At 1 h, these proportions were 458% of patients in the
oxymetazoline group compared with 98% of patients in the
vehicle group; at 3 h, 802% vs. 195%; at 6 h, 745% vs.
229%; at 9 h, 634% vs. 214% and at 12 h, 542% vs.
179%. At least a marked (~75% or greater) erythema reduc-
tion was achieved in up to 436% of patients treated with
oxymetazoline vs. 71% for those treated with vehicle. Figure 3
shows photographs of a patient from the oxymetazoline group
who achieved moderate (~50%) or marked (~75%) reduction
or complete clearing (~95%) in erythema at different time
points.
The percentage erythema reduction scores had a strong nega-
tive correlation with the CEA scores (Spearman rank correlation
07084; P < 0001), indicating a high level of agreement
between these methods of assessment. The majority of pho-
tographs rated as showing ~95% erythema improvement com-
pared with baseline were assigned CEA scores of 0 or 1 (931%,
148 of 159). Similar observations were made for photographs
showing ~75% erythema improvement [CEA scores of 1 or 2
(908%, 484 of 533)], ~50% improvement [CEA scores of 2 or
3 (859%, 869 of 1012)], ~25% improvement [CEA scores of 2
or 3 (871%, 758 of 870)] and no improvement [CEA scores of
3 or 4 (935%, 1497 of 1601)].
Correlation with patient satisfaction
Patient satisfaction levels with their facial skin redness in the
phase III trials correlated with the percentage of erythema
improvement from the phase IV study (Fig. 4). This associa-
tion was statistically significant for patients treated with
oxymetazoline (Spearman rank correlation 01824; P < 0001)
and for patients treated with vehicle (Spearman rank correla-
tion 00623; P = 001). Of 136 patients in the oxymetazoline
group who had ~95% erythema improvement, approximately
40% (54 patients) were satisfied (47 patients) or very satisfied
(seven patients), and 36% (49 patients) reported their satisfac-
tion level as acceptable. In contrast, only eight patients in the
vehicle group had ~95% erythema improvement and 25%
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compared with the phase III trials for patients in the oxymetazoline group and the vehicle group (merged population). CEA scale: 0, clear; 1,
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(two patients) reported being very satisfied. Among each sub-
set of patients treated with vehicle whose percentage of ery-
thema improvement was ~75% or less, more than half
consistently reported dissatisfaction with their facial skin red-
ness. In general, in the oxymetazoline group, as the percent-
age of erythema improvement with oxymetazoline increased,
so did the satisfaction levels of patients.
Fitzpatrick skin phototype analysis
As in the overall study population, the proportions of patients
who achieved at least a 1-grade CEA improvement in the Fitz-
patrick skin phototype subgroups I–III and IV–VI were signifi-
cantly greater in the oxymetazoline group than in the vehicle
group (Fig. 5). In the subgroup of patients with Fitzpatrick skin
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3 Hours 
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6 Hours 
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9 Hours 
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12 Hours 
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CEA Phase IV 3Phase III 3
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Fig 2. Representative photographs of a patient with rosacea from the oxymetazoline group (a) and a patient from the vehicle group (b). The
Clinician Erythema Assessment (CEA) improvements for the patient treated with oxymetazoline were the same in both trials. Although the CEA
assessments for the patient in the vehicle group demonstrated improvement in the phase III trial, they showed no improvement when the
investigator was able to refer to the baseline photograph while evaluating post-treatment photographs (phase IV). CEA scale: 0, clear; 1, almost
clear; 2, mild erythema; 3, moderate erythema; 4, severe erythema. , CEA ≥ 1-grade improvement.
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Fig 3. Photographs of a patient with rosacea from the oxymetazoline group with representative percentage improvements in erythema from
baseline on day 1. Percentage improvement scale for reduction in erythema: 0, none; ~25%, mild; ~50%, moderate; ~75%, marked; ~95%,
complete clearing.
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phototype I–III, up to 851% of patients in the oxymetazoline
group had at least a 1-grade CEA improvement compared with
278% of patients in the vehicle group (P < 0001). Similarly,
in the subgroup of patients with skin phototype IV–VI, up to
919% of patients treated with oxymetazoline achieved this level
of improvement in CEA, compared with 255% of patients trea-
ted with vehicle (P < 0001).
Worsening of erythema
On day 1, fewer than 1% of patients (072%, three of 415) in
the oxymetazoline group were assessed as having at least a
1-grade increase in CEA, indicating worsening erythema, com-
pared with 548% (23 of 420) in the vehicle group. When
reference to the baseline photograph was not allowed, the pro-
portion of patients who were considered to have at least a
1-grade CEA increase was 247% (11 of 446) in the oxymetazo-
line group and 524% (23 of 439) in the vehicle group.
Discussion
In this photographic study of topical once-daily oxymetazoline
10% cream, investigators evaluated erythema severity in pho-
tographs from the REVEAL pivotal phase III trials, with refer-
ence to the baseline photograph. More than 60% of patients
achieved at least a 1-grade CEA improvement that persisted at
least 12 h after application of oxymetazoline. Notably, the
proportions of patients achieving the same outcome with
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vehicle were substantially lower when investigators were
allowed to refer to the baseline photograph than in the phase
III trials, in which live, static assessments were made (up to
432% lower). The introduction of a baseline photograph into
the methodology for evaluating erythema severity resulted in
an apparent mitigation of the vehicle effect, perhaps allowing
better visualization of lack of improvement. At the same time,
the use of photography in the CEA assessments did not distort
the results for oxymetazoline; proportions of patients who
achieved at least a 1-grade improvement in CEA from baseline
with oxymetazoline remained consistent between the trials.
The lack of access to the baseline photographs during the
live patient assessments in the phase III trials may have inflated
the results for vehicle. Improvements with vehicle treatment
have been a documented limitation of randomized controlled
clinical trials investigating new drugs for dermatological dis-
eases, including rosacea.17–21 Raters, blinded to the study
treatment, may seek out the expected effects of the active drug
treatment from the vehicle treatment, artificially identifying a
response to vehicle where none exists.22 The vehicle control is
inherent to the design of clinical trials to support new rosacea
drug approvals by the U.S. Food and Drug Administration, as
is the live, static assessment of efficacy measures, i.e. assess-
ment based on physical examination of patients at study visits
with no reference to other time points in the study, such as
baseline.13–15 This study has demonstrated that the review of
photography – in particular, reference to a baseline pho-
tograph – may enhance the evaluation of the efficacy of a
topical treatment for persistent erythema of rosacea, poten-
tially resulting in more accurate assessments for vehicle.
Randomized controlled clinical trials of therapies for other
dermatological conditions also may include evaluation of
patient photographs to assess efficacy. In trials of topical, oral,
and laser treatments for hair loss, efficacy has been evaluated
through review of standardized baseline and post-treatment
photographs.23–27 This global approach to photographic
assessment is also used in the study of therapies for scarring
and hyperpigmentation.28–30 The results of this study suggest
that similar methodology should be incorporated into the
design of clinical trials to support approval for treatments of
persistent facial erythema.
Another consequence of the lack of access to baseline pho-
tographs in the REVEAL trials may have been differences in
the proportions of patients who had at least a 1-grade increase
in CEA, indicating worsening erythema. The same number of
patients treated with vehicle experienced this increase in CEA,
but fewer patients treated with oxymetazoline were deemed to
have worsening erythema when reference to the baseline pho-
tograph was allowed. These observations underscore the
importance of the comparison to baseline in the accuracy of
assessments of erythema severity.
A limitation of this study is that it analysed only frontal
facial photographs, negating assessment of the lateral aspect of
the cheeks. In photographs, it may be more difficult to distin-
guish the telangiectasia of rosacea from background erythema,
which may result in underestimating the level of erythema
improvement. Other factors that could affect the appearance
of the patient in a photograph include photographic filters,
lighting in the room and the patient’s physical state. Addition-
ally, worsening of erythema may have been more difficult to
assess in patients with severe erythema at baseline, because
the CEA scale does not allow a higher rating for erythema
beyond fiery redness.
Whether darker skin pigment contributed to the poorer
assessments for vehicle in this study is one concern, as ery-
thema may be less detectable in darker skin.31 However, the
results in patients with Fitzpatrick skin phototype subgroups
(I–III and IV–VI) echoed the findings in the overall phase IV
study population. The percentage of patients who had at least
a 1-grade improvement in CEA was substantially lower with
vehicle than with oxymetazoline, regardless of phototype. The
data were consistent with unpublished analyses indicating that
efficacy of topical oxymetazoline cream in patients with per-
sistent erythema of rosacea was similar in subgroups of
patients with Fitzpatrick skin phototypes I–III and those with
types IV–VI (data on file, Allergan plc). The visible improve-
ment in facial erythema even in patients with darker skin col-
our that was noted in these studies is encouraging, as effective
treatment of rosacea in patients with skin of colour is needed.
In this study, a greater percentage of patients achieved
improvement in persistent facial erythema of rosacea from
baseline on the first day of application with oxymetazoline
than with vehicle when investigators were allowed to refer-
ence the patient’s baseline photograph while evaluating post-
treatment photographs to assess erythema severity over time.
The results were similar to those in the oxymetazoline arms of
the phase III trials, but there was a significantly less pro-
nounced vehicle effect. These observations suggest that this
methodology, which allows for comparison to baseline
photographs, may improve the accuracy of clinical trials that
evaluate erythema severity.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website:
Fig S1. Monitor and data capture set-up. Investigators were
blinded to the sequence of presentation of photographs.
Fig S2. Proportions of patients with rosacea with at least a
1-grade Clinician Erythema Assessment (CEA) scale improve-
ment (per-protocol population). 0, clear; 1, almost clear; 2,
mild erythema; 3, moderate erythema; 4, severe erythema.
aP < 0001 for the comparison to vehicle.
Fig S3. Proportion of patients with erythema improvement
of ~50%, ~75% and/or ~95% at each time point (per-proto-
col population). Percentage improvement scale for reduction
in erythema: 0, none; ~25%, mild; ~50%, moderate; ~75%,
marked; ~95%, complete clearing. aP < 0001 for the compar-
ison to vehicle.
Table S1 Clinician Erythema Assessment (CEA) scale and
percentage of erythema improvement scale descriptions.
Table S2 Patient demographics and baseline clinical charac-
teristics (per-protocol population).
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